Search Results - "DISAIA, Philip J"

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer by Tewari, Krishnansu S, Burger, Robert A, Enserro, Danielle, Norquist, Barbara M, Swisher, Elizabeth M, Brady, Mark F, Bookman, Michael A, Fleming, Gini F, Huang, Helen, Homesley, Howard D, Fowler, Jeffrey M, Greer, Benjamin E, Boente, Matthew, Liang, Sharon X, Ye, Chenglin, Bais, Carlos, Randall, Leslie M, Chan, John K, Ferriss, J Stuart, Coleman, Robert L, Aghajanian, Carol, Herzog, Thomas J, DiSaia, Philip J, Copeland, Larry J, Mannel, Robert S, Birrer, Michael J, Monk, Bradley J

“…We report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly…”
Get full text

Fertility preserving options in patients with gynecologic malignancies by Eskander, Ramez N., MD, Randall, Leslie M., MD, Berman, Michael L., MD, Tewari, Krishnansu S., MD, Disaia, Philip J., MD, Bristow, Robert E., MD

“…A proportion of reproductive age women are affected by gynecologic malignancies. This patient population is faced with difficult decisions, related to their…”
Get full text

Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: A multivariate analysis by Chan, John K, Sugiyama, Valerie, Pham, Huyen, Gu, Mai, Rutgers, Joanne, Osann, Kathryn, Cheung, Michael K, Berman, Michael L, DiSaia, Philip J

“…Abstract Objectives. To determine the importance of margin status and other prognostic factors associated with the recurrence and survival of patients with…”
Get full text

Colposcopy to evaluate abnormal cervical cytology in 2008 by Chase, Dana M., MD, Kalouyan, Marlene, BS, DiSaia, Philip J., MD

“…The rates of cervical cancer in the United States are low in comparison with developing nations. Whereas the Papanicolaou smear has performed well in terms of…”
Get full text

NRG Oncology Research Opportunities Within the New National Clinical Trials Network by Curran, Walter J., MD, DiSaia, Philip J., MD, Wolmark, Norman, MD

Get full text

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) by Tewari, Krishnansu S, Sill, Michael W, Penson, Richard T, Huang, Helen, Ramondetta, Lois M, Landrum, Lisa M, Oaknin, Ana, Reid, Thomas J, Leitao, Mario M, Michael, Helen E, DiSaia, Philip J, Copeland, Larry J, Creasman, William T, Stehman, Frederick B, Brady, Mark F, Burger, Robert A, Thigpen, J Tate, Birrer, Michael J, Waggoner, Steven E, Moore, David H, Look, Katherine Y, Koh, Wui-Jin, Monk, Bradley J

“…On Aug 14, 2014, the US Food and Drug Administration approved the antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis of…”
Get full text

Phase II Trial of Gemcitabine plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Ovarian Cancer Patients by Nagourney, Robert A., Brewer, Cheryl A., Radecki, Stephen, Kidder, Wesley A., Sommers, Barbara L., Evans, Steven S., Minor, David R., DiSaia, Philip J.

“…Objectives. The aim was to determine the safety and efficacy of gemcitabine plus cisplatin for patients with relapsed ovarian carcinoma and to compare ex vivo…”
Get full text

Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study by Copeland, Larry J, Brady, Mark F, Burger, Robert A, Rodgers, William H, Huang, Helen Q, Cella, David, O'Malley, David M, Street, Daron G, Tewari, Krishnansu S, Bender, David P, Morris, Robert T, Lowery, William J, Miller, David S, Dewdney, Summer B, Spirtos, Nick M, Lele, Shashikant B, Guntupalli, Saketh, Ueland, Frederick R, Glaser, Gretchen E, Mannel, Robert S, DiSaia, Philip J

“…To compare taxane maintenance chemotherapy, paclitaxel (P) and paclitaxel poliglumex (PP), with surveillance (S) in women with ovarian, peritoneal, or…”
Get full text

Predicting Parametrial Involvement in Endometrial Cancer: Is This the End for Radical Hysterectomies in Stage II Endometrial Cancers? by DiSaia, Philip J.

Get full text

Differences in Prognostic Molecular Markers between Women Over and Under 45 Years of Age with Advanced Ovarian Cancer by CHAN, John K, LOIZZI, Vera, MAGISTRIS, Alessandra, LIN, Fritz, RUTGERS, Joanne, OSANN, Kathryn, DISAIA, Philip J, BERMAN, Michael L

“…Purpose: The purpose of this study was to determine whether differences in molecular markers might explain the better prognosis of women ≤45 years of age…”
Get full text

Node count and groin recurrence in early vulvar cancer: A Gynecologic Oncology Group study by Stehman, Frederick B, Ali, Shamshad, DiSaia, Philip J

“…Abstract Objective To determine if low node count from superficial groin dissection correlated with first recurrence in the groin for patients with early…”
Get full text

Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer by Chan, John K., Magistris, Alessandra, Loizzi, Vera, Lin, Fritz, Rutgers, Joanne, Osann, Kathryn, DiSaia, Philip J., Samoszuk, Michael

“…To determine clinical or biological associations between mast cell density, blood clotting, angiogenesis, and survival of patients with advanced ovarian…”
Get full text

Prognostic factors responsible for survival in sex cord stromal tumors of the ovary—A multivariate analysis by Chan, John K., Zhang, Mallory, Kaleb, Vanessa, Loizzi, Vera, Benjamin, Jacqueline, Vasilev, Steve, Osann, Kathryn, DiSaia, Philip J.

“…To evaluate prognostic factors that impacts the survival of women with sex cord stromal tumors of the ovary (SCST). Cases were identified from tumor registry…”
Get full text

Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay–guided chemotherapy by Loizzi, Vera, Chan, John K, Osann, Kathryn, Cappuccini, Fabio, DiSaia, Philip J, Berman, Michael L

“…The purpose of this study was to determine the outcome of patients with recurrent ovarian carcinoma after extreme drug resistance assay-directed therapy. Fifty…”
Get full text

Treatment of ovarian cancer: new strategies by DiSaia, Philip J, Bloss, Jeffrey D

“…The objective was to review the progress made in gene- and molecular-based management of ovarian cancer over the past decade and the future direction of…”
Get full text

Estrogen replacement therapy in endometrial cancer patients:: A matched control study by Suriano, Kimberly A, McHale, Michael, McLaren, Christine E, Li, Kuo-Tung, Re, Alessandra, DiSaia, Philip J

“…Objective: To determine if estrogen replacement therapy, in women with a history of endometrial cancer, increases the risk of recurrence or death from that…”
Get full text

Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? by Chan, John K, Loizzi, Vera, Lin, Yvonne G, Osann, Kathryn, Brewster, Wendy R, DiSaia, Philip J

“…To compare the survival rates in younger (45 years or younger) and older women (over 45) diagnosed with advanced-stage invasive epithelial ovarian cancer…”
Get full text

Malignant germ cell tumors of the ovary by Tewari, Krishnansu, Cappuccini, Fabio, Disaia, Philip J, Berman, Michael L, Manetta, Alberto, Kohler, Matthew F

“…Objective: To evaluate the efficacy of adjuvant therapy for ovarian germ cell tumors. Methods: We reviewed records of women who had malignant germ cell tumors…”
Get full text

Clinicopathologic features of six cases of primary cervical lymphoma by Chan, John K., Loizzi, Vera, Magistris, Alessandra, Hunter, Mark I., Rutgers, Joanne, DiSaia, Philip J., Berman, Michael L.

“…Primary lymphoma of the uterine cervix is rare, with less than 60 cases reported. We present a series of 6 patients with cervical lymphoma and review the…”
Get full text

Hormone replacement and breast cancer risk: reconsidering the data by Creasman, William T, DiSaia, Philip J

Get more information